Literature DB >> 12624626

No association between thrombosis and factor V gene polymorphisms in Chinese Han population.

Hu Yanqing1, Chen Fangping, Xie Qinzhi, Jian Zaifu, Wang Guangping, Zuo Xiaoxia, Pu Xiaoqun.   

Abstract

Activated protein C resistance (APCR) is the most common hereditary condition of thrombosis in Western countries. And it is significantly linked to a single nucleotide polymorphisms (SNPs) in the coagulation factor V gene that results in the mutations at R506, R306 and HR2 alleles. To determine the prevalence of APCR and its association with the factor V gene SNPs in Chinese Han thrombotic patients, we investigated a total of 346 Chinese thrombotic patients and 140 normal controls for APCR using the APTT-based assays, according to manufacturer's instructions, APC ratio </=2 indicated APC resistance. Mutations of factor V at R506, R306, HR2 allele were detected by PCRMnl/I, Bst/NI, Rsa/I digestion as described before respectively. The results showed that the incidence of APC resistance were 12.0% (12 of 100 cases) in acute cerebral thrombosis (ACT) patients (P <0.05), 13.5% (13 of 96 cases) in acute myocardial infarction (AMI) patients (P <0.05), 16.7% (10 of 60 cases) in deep venous thrombosis (DVT) patients (P <0.05), 15.6% (14 of 90 cases) in systemic lupus erythematosus (SLE) patients (P <0.05) and 5.0% (7 of 140 cases) in normal controls. APCR is associated with thrombotic events. But no factor V R506Q mutation (FV Leiden) was found in all 5 groups. Only one AMI patient and one DVT patient revealed heterozygous R306G mutation, which was confirmed by direct sequencing PCR products. Additionally, two SLE patients showed to be heterozygous HR2 allele for the first time in the Chinese Han population. We concluded that APC resistance in the Chinese Han population might not be associated with mutations of factor V at R506, R306 and HR2 polymorphisms. Some other factors might contribute to APC resistance in the Chinese Han population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12624626

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Normal ranges and genetic variants of antithrombin, protein C and protein S in the general Chinese population. Results of the Chinese Hemostasis Investigation on Natural Anticoagulants Study I Group.

Authors:  Tienan Zhu; Qiulan Ding; Xia Bai; Xiaoyan Wang; Florentia Kaguelidou; Corinne Alberti; Xuqian Wei; Baolai Hua; Renchi Yang; Xuefeng Wang; Zhaoyue Wang; Changgeng Ruan; Nicole Schlegel; Yongqiang Zhao
Journal:  Haematologica       Date:  2011-04-12       Impact factor: 9.941

Review 2.  Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai).

Authors: 
Journal:  J Dig Dis       Date:  2021-03-07       Impact factor: 2.325

3.  Risk of Budd-Chiari syndrome associated with factor V Leiden and G20210A prothrombin mutation: a meta-analysis.

Authors:  Peijin Zhang; Jing Zhang; Guixiang Sun; Xiuyin Gao; Hui Wang; Wenjun Yan; Hao Xu; Maoheng Zu; He Ma; Wei Wang; Zhaojun Lu
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

4.  Splenectomy Causes 10-Fold Increased Risk of Portal Venous System Thrombosis in Liver Cirrhosis Patients.

Authors:  Xingshun Qi; Guohong Han; Chun Ye; Yongguo Zhang; Junna Dai; Ying Peng; Han Deng; Jing Li; Feifei Hou; Zheng Ning; Jiancheng Zhao; Xintong Zhang; Ran Wang; Xiaozhong Guo
Journal:  Med Sci Monit       Date:  2016-07-19

Review 5.  Familial Budd-Chiari Syndrome in China: A Systematic Review of the Literature.

Authors:  Xingshun Qi; Juan Wang; Weirong Ren; Ming Bai; Man Yang; Guohong Han; Daiming Fan
Journal:  ISRN Hepatol       Date:  2013-02-28

6.  Factor V Leiden, factor V Cambridge, factor II GA20210, and methylenetetrahydrofolate reductase in cerebral venous and sinus thrombosis: A case-control study.

Authors:  Mohammad Saadatnia; Mansour Salehi; Ahmad Movahedian; Seyed Ziaeddin Samsam Shariat; Mehri Salari; Marzieh Tajmirriahi; Elham Asadimobarakeh; Rasoul Salehi; Gilda Amini; Homa Ebrahimi; Ehsan Kheradmand
Journal:  J Res Med Sci       Date:  2015-06       Impact factor: 1.852

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.